Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 2/20 | 0.49 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4382927 | 1.00 | P2RX3 (0.49) | P2RX3P2RX2KMT2ADHFRPOLB | |
| SCHEMBL5669548 | 0.83 | DHFR (0.43) | P2RX3P2RX2DHFR | |
| SCHEMBL23931351 | 0.83 | P2RX3 (0.47) | P2RX3P2RX2DHFRPOLB | |
| SCHEMBL23931355 | 0.81 | P2RX3 (0.44) | P2RX3P2RX2DHFR | |
| SCHEMBL19813184 | 0.81 | P2RX3 (0.44) | P2RX3P2RX2DHFR | |
| SCHEMBL5860694 | 0.79 | P2RX3 (0.43) | P2RX3P2RX2DHFRPOLB | |
| SCHEMBL8378083 | 0.79 | P2RX3 (0.42) | P2RX3P2RX2DHFR | |
| SCHEMBL27991633 | 0.78 | P2RX3 (0.46) | P2RX3P2RX2DHFRPOLB | |
| SCHEMBL28170660 | 0.76 | KMT2A (0.44) | KMT2ADHFR | |
| SCHEMBL16966453 | 0.75 | P2RX3 (0.46) | P2RX3P2RX2DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550473-B2 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20050124640-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124640-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | PRKCQ, PRKCZ, PRKCH | P2RX3 513/4885P2RX2 357/4885KMT2A 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.